Zobrazeno 1 - 6
of 6
pro vyhledávání: '"The Primary Health Care Group Of Salamanca For The Study Of Mbl"'
Autor:
Ignacio Criado, Arancha Rodríguez-Caballero, M. Laura Gutiérrez, Carlos E. Pedreira, Miguel Alcoceba, Wendy Nieto, Cristina Teodosio, Paloma Bárcena, Alfonso Romero, Paulino Fernández-Navarro, Marcos González, Julia Almeida, Alberto Orfao, The Primary Health Care Group of Salamanca for the Study of MBL
Publikováno v:
Haematologica, Vol 103, Iss 7 (2018)
Low-count monoclonal B-cell lymphocytosis is defined by the presence of very low numbers of circulating clonal B cells, usually phenotypically similar to chronic lymphocytic leukemia cells, whose biological and clinical significance remains elusive.
Externí odkaz:
https://doaj.org/article/c34e214cda1d47658a35f21496546253
Autor:
Ignacio, Criado, Wendy G, Nieto, Guillermo, Oliva-Ariza, Blanca, Fuentes-Herrero, Cristina, Teodosio, Quentin, Lecrevisse, Antonio, Lopez, Alfonso, Romero, Julia, Almeida, Alberto, Orfao, The Primary Health Care Group Of Salamanca For The Study Of Mbl
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 58
Reference ranges of blood-circulating leukocyte populations by, e.g., age and sex, are required for monitoring immune-cell kinetics. Most previous reports in which flow cytometry has been used to define the reference ranges for leukocyte counts inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677d263fa34a7a2186b76af2fd3827c8
Autor:
Delphine Casabonne, Julia Almeida, Wendy G Nieto, Alfonso Romero, Paulino Fernández-Navarro, Arancha Rodriguez-Caballero, Santiago Muñoz-Criado, Marcos González Díaz, Yolanda Benavente, Silvia de Sanjosé, Alberto Orfao, Primary Health Care Group of Salamanca for the Study of MBL
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e52808 (2012)
BACKGROUND: Risk factors associated with monoclonal B-cell lymphocytosis (MBL), a potential precursor of chronic lymphocytic leukaemia (CLL), remain unknown. METHODS: Using a cross-sectional study design, we investigated demographic, medical and beha
Externí odkaz:
https://doaj.org/article/78926a17512a4c73ba118b3ea5f89193
Autor:
Delphine Casabonne, Julia Almeida, Wendy G. Nieto, Alfonso Romero, Paulino Fernández-Navarro, Arancha Rodriguez-Caballero, Santiago Muñoz-Criado, Marcos González Díaz, Yolanda Benavente, Silvia de Sanjosé, Alberto Orfao, the Primary Health Care Group of Salamanca for the Study of MBL
Publikováno v:
PLoS ONE, Vol 8, Iss 10 (2013)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::706cc96808bef59fefb18649cbeed1d9
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795778/?tool=EBI
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795778/?tool=EBI
Autor:
Casabonne, Delphine, Almeida, Julia, Nieto, Wendy G, Romero, Alfonso, Fernández Navarro, Paulino, Rodriguez Caballero, Arancha, Munoz Criado, Santiago, González Díaz, Marcos, Benavente, Yolanda, Sanjosé Llongueras, Silvia de, Orfao, Alberto, Primary Health Care Group of Salamanca for the Study of MBL
Publikováno v:
PLoS ONE
Recercat. Dipósit de la Recerca de Catalunya
instname
Digital.CSIC. Repositorio Institucional del CSIC
Dipòsit Digital de la UB
Universidad de Barcelona
PLoS ONE, Vol 7, Iss 12, p e52808 (2012)
Recercat. Dipósit de la Recerca de Catalunya
instname
Digital.CSIC. Repositorio Institucional del CSIC
Dipòsit Digital de la UB
Universidad de Barcelona
PLoS ONE, Vol 7, Iss 12, p e52808 (2012)
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- Primary Health Care Group of Salamanca for the Study of MBL: et al.
[Background]: Risk factors associated with monoclonal B-cell lymphocyto
[Background]: Risk factors associated with monoclonal B-cell lymphocyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8786569ff03c0c7a949350394eb61421
http://europepmc.org/articles/PMC3532166
http://europepmc.org/articles/PMC3532166
Autor:
Criado I; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain., Nieto WG; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain., Oliva-Ariza G; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain., Fuentes-Herrero B; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain., Teodosio C; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain., Lecrevisse Q; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain., Lopez A; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain., Romero A; Centro de Atención Primaria de Salud Miguel Armijo, Sanidad de Castilla y León (SACyL), 37007 Salamanca, Spain., Almeida J; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain., Orfao A; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-Universidad de Salamanca); Cytometry Service, NUCLEUS; Departamento de Medicina, Universidad de Salamanca (https://ror.org/02f40zc51) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain., The Primary Health Care Group Of Salamanca For The Study Of Mbl
Publikováno v:
Cancers [Cancers (Basel)] 2022 Dec 22; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 22.